Karyopharm Therapeutics Inc. - KPTI STOCK NEWS

Karyopharm Therapeutics (KPTI) reported second-quarter 2020 financial results, achieving record sales of $18.6 million for XPOVIO despite ongoing COVID-19 challenges. The FDA granted accelerated approval for XPOVIO to treat relapsed DLBCL, marking it as the only oral agent for this indication. The company announced a significant 16% sales increase from Q1 2020 and reported a 47% improvement in progression-free survival in a key clinical study. However, Karyopharm faced a net loss of $46.4 million, largely influenced by increased R&D expenses.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced on August 3, 2020, the grant of stock options to purchase 27,300 shares of its common stock to three newly-hired employees, effective July 31, 2020. The options have an exercise price of $16.05 per share, equivalent to the closing price on the grant date. These stock options will vest over four years, with 25% vesting on the first anniversary of employment. In case of a change in control event, employees can fully exercise options if terminated for good reason or without cause.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will announce its second quarter 2020 financial results on August 4, 2020. A conference call is scheduled for 8:30 a.m. ET the same day, allowing investors to discuss the results and company updates. The company is known for its innovation in pharmaceutical development, particularly its lead compound, XPOVIO®, which has FDA approval for treating multiple myeloma and diffuse large B-cell lymphoma. Investors can access the live audio webcast through Karyopharm's [Investor section](http://investors.karyopharm.com/events-presentations).

Karyopharm Therapeutics (Nasdaq: KPTI) announced that the FDA has accepted its supplemental New Drug Application (sNDA) for XPOVIO (selinexor) as a treatment for multiple myeloma after at least one prior line of therapy. The FDA decision is expected by the end of Q1 2021. XPOVIO, already approved for penta-refractory multiple myeloma and relapsed diffuse large B-cell lymphoma, aims to broaden its patient base. Karyopharm intends to submit a Marketing Authorization Application to the European Medicines Agency for this indication.

Karyopharm Therapeutics (Nasdaq: KPTI) announced a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to advance XPOVIO (selinexor), a first-in-class oral cancer treatment. The partnership aims to explore XPOVIO's efficacy across various cancer types, supported by promising anti-tumor activity from previous studies. Currently approved for relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma, XPOVIO has a supplemental FDA application for expanded treatment indications. Karyopharm is dedicated to addressing significant unmet medical needs in oncology.

Karyopharm Therapeutics (Nasdaq: KPTI) reported preliminary unaudited net product sales of approximately $18.5 million for its oral cancer treatment XPOVIO in Q2 2020, marking a 15% increase from Q1 2020, the highest quarterly sales since its launch in July 2019. Despite challenges from the COVID-19 pandemic, demand from healthcare providers remains strong. The FDA recently granted accelerated approval for XPOVIO in treating relapsed or refractory diffuse large B-cell lymphoma, following promising Phase 3 study results for multiple myeloma. Full financial results will be announced in August.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the grant of stock options to purchase 41,700 shares of its common stock to eight new employees as part of their inducement for joining the company. The options, priced at $18.94 per share, were approved by the Compensation Committee on June 30, 2020, in compliance with Nasdaq Listing Rule 5635(c)(4). These options vest over four years with specific conditions regarding termination tied to a change in control event. Karyopharm is focused on developing innovative treatments for cancer and other major diseases.

Karyopharm Therapeutics (KPTI) announced positive results from the Phase 2b SADAL study, assessing XPOVIO (selinexor) for relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL). The study reported an overall response rate of 28%, with a complete response rate of 12%. Notably, the median duration of response was 9.3 months. FDA approved XPOVIO for this indication on June 22, 2020, under the Accelerated Approval Program. A European submission is planned for 2021, further extending its market potential.

Karyopharm Therapeutics announced FDA approval for XPOVIO® (selinexor), now the only single-agent oral therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This first-in-class drug also holds the distinction of being the only FDA-approved treatment for both DLBCL and multiple myeloma. The approval comes under the FDA’s Accelerated Approval Program, based on a 29% overall response rate in clinical studies. XPOVIO will be available immediately in the U.S., with plans for a European submission in 2021. Continued approval depends on further clinical trials to confirm its benefits.